eClinical Technology and Industy News

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Treatment for Obsessive-Compulsive Disorder

Excerpt from the Press Release:

BURLINGTON, MA and JERUSALEM, Israel, January 12, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced key research data published in two leading peer-reviewed industry journals highlighting the durability and cost-effectiveness of its proprietary Deep TMS™ treatment for patients coping with obsessive-compulsive disorder (OCD).

While prior research has demonstrated the safety and efficacy of Deep TMS in treating OCD, a recent study published in Brain Stimulation now shows the durability of Deep TMS and the significant reduction in functional disability. Additionally, positive data published in the Journal of Psychiatric Research support the cost-effectiveness of Deep TMS relative to other available treatment options for OCD.

To evaluate the durability of the Deep TMS OCD treatment, clinical sites from the Company’s pivotal trial, as well as those that contributed post-marketing data, conducted follow up assessments with patients that had met response criteria following treatment with the H7 Coil. Durability was defined as the elapsed time from the end of the Deep TMS treatment course until there was a change in ongoing treatment. Data revealed that of the 60 subjects evaluated from seven clinical sites, 52 demonstrated durability of one year or more (86.7%), 26 of which showed two or more years of durability. Moreover, the data showed that patients exhibited a significant reduction in disability. Self-reported unproductive days per week dropped from 5.5 days (±0.4) to 1.8 days (±0.4). Additionally, self-reported lost days per week dropped from 1.9 (±0.6) to 0.3 days (±0.2).

“In our ongoing discussions with payors, there is significant interest in not only the clinically proven safety and efficacy of Deep TMS for OCD, but also the demonstrated durability,” said Scott Blackman, Director of Market Access for BrainsWay. “These durability results, coupled with the compelling reduction in functional disability, help reinforce the utility of this technology for patients suffering from OCD.”

Furthermore, positive data recently published in the Journal of Psychiatric Research demonstrated the relative cost-effectiveness of Deep TMS for refractory OCD patients when compared with other treatments within the treatment continuum, which includes outpatient medication management and cognitive-behavioral therapy (CBT), as well as more intensive, facility-based approaches. The data suggest that Deep TMS is a cost-effective alternative, and particularly indicate that it may serve as an incremental strategy to employ when higher intensity strategies, such as facility-based approaches, are either unavailable, not financially feasible, or have extended waits for admission.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?